Austria’s Biotech Future in Focus: NovoArc Hosts Federal Leaders

We were honored to welcome Federal Minister Dr. Wolfgang Hattmannsdorfer, Bundesvorsitzende der Jungen Wirtschaft Bettina Dorfer-Pauschenwein, and their teams from the Federal Ministry for Economic Affairs and Energy and the Austrian Federal Economic Chamber to NovoArc GmbH. We opened our doors to showcase our proprietary archaeal lipid technology, state-of-the-art laboratories, and the team behind our innovation.

 

Together, we explored how Austria can evolve from a nation of strong research excellence into a global market leader by fostering translational capabilities, scaling manufacturing capacity, and encouraging cross-border collaborations. Strengthening commercialization pathways and venture support for emerging biotech companies was identified as key to bridging the gap between the lab and the global marketplace.

During the visit, we also presented our product portfolio demonstrating how our lipid systems enhance stability, bioavailability, and formulation flexibility for next-generation therapeutics. The future of biotech innovation depends on people. We reflected on how Austria can nurture a new generation of talent with the interdisciplinary skills essential for bioprocessing, data-driven biotechnology, and analytical platforms. As a company committed to bridging science and application, we take pride in contributing to Austria’s growing biotech ecosystem transforming fundamental research into impact, one breakthrough at a time.

News

NovoArc 4th Anniversary: Science, Teamwork & Celebration

Four years of bridging science and application.

Read more
Lipidosa Project: advancing oral delivery of challenging APIs with tetraetherlipid formulations.

Lipidosa Project Kick-Off

We are excited to announce the start of our Lipidosa Project in colaboration with Joanneum Graz, running from July 2025 to June 2027, focused on the pharmacological characterization of tetraetherlipid formulations for oral administration.

One of the greatest challenges in drug development is ensuring that active pharmaceutical ingredients (APIs) reach their target in the body at the right place, in the right dosage, and at the right time.

While oral administration is the most conveniat, and most preferred route for patients, many promising APIs face critical limitations: degradation in the harsh environment of the digestive tract or insufficient absorption across the intestinal barrier. These issues lead to poor bioavailability, preventing their full therapeutic potential from being realized.

Through Lipidosa, NovoArc aims to unlock new possibilities for stable and efficient oral drug delivery by leveraging our unique tetraetherlipid technology.

D2R Project Spotlight: NovoArc contributing lipid innovation for next-generation mRNA vaccine delivery.

NovoArc Joins D2R Project Spotlight Collaboration

We are proud to announce our participation in the D2R Project Spotlight, a collaborative effort with leading researchers from McGill University, Dalhousie University, the University of Calgary, and RNA Technologies and Therapeutics.
This project focuses on the development of a rapid antigen identification platform, with the aim of accelerating next-generation mRNA vaccine development and enabling faster responses to emerging infectious diseases an urgent need that remains highly relevant in the post-COVID era.
As part of this initiative, NovoArc contributes its lipid-based formulation technology to advance innovative solutions for efficient mRNA vaccine delivery.

Read more
Oliver Spadiut presenting NovoArc’s lipid innovation at Advanced Therapies 2025 in London.

NovoArc Showcased at Advanced Therapies 2025

We are proud to share that our Co-founder and CPO, Oliver Spadiut, delivered an inspiring talk during the Innovation Session at the Advanced Therapies Conference 2025 in London.

He presented how NovoArc’s next-generation lipid platform is redefining drug delivery by enabling the oral administration of biologics, small molecules, and nucleic acids.

Key insight from the session: Stability and efficient delivery remain central challenges in therapeutic development. NovoArc’s lipid technology offers a breakthrough solution to address these barriers and unlock new possibilities in advanced therapies.

NovoArc GmbH has won the Phönix Start-up Award!

NovoArc GmbH has won the Phönix Start-up Award! Receiving this prestigious prize at the Haus der Industrie Industriellenvereinigung was an unforgettable moment in an amazing atmosphere – a recognition of the hard work we’ve put in over the past years.

Read more

Meet us at BIO-Europe 2024

Excited to be attending BIO-Europe in Stockholm, Sweden from November 4–6, 2024! Looking forward to connecting and exchanging insights. See you there!